GHRP-2: What the Evidence Actually Shows

GHRP-2 — growth hormone-releasing peptide-2, also known by its generic drug name pralmorelin — is sold in the peptide research market as a GH-boosting secretagogue alongside compounds like ipamorelin and sermorelin. What that framing usually skips is a real, specific regulatory split this article checked directly rather than assumed: GHRP-2 has an established clinical diagnostic use in Japan, and a genuinely serious FDA safety-page entry in the United States — two different, both-real facts about the same molecule, not a contradiction to resolve into one verdict.

What it actually is

GHRP-2 is a synthetic pentapeptide (D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2) that activates the ghrelin receptor (GHSR-1a), the same receptor ghrelin itself binds, triggering pituitary GH release through a mechanism distinct from GHRH-receptor agonists like sermorelin or CJC-1295. It was developed under the research code GPA-748 by Wyeth-Ayerst — a detail worth naming because it corrects the common assumption that every compound in this market started as an underground research-chemical invention; GHRP-2 began as major-pharma drug development³. A direct human comparison study found GHRP-2 and hexarelin — a related, more potent hexapeptide covered in this site's own Hexarelin evidence review — produce a similar, strong, dose-dependent GH response when given intravenously to healthy adults, stronger than a standard GHRH dose at the tested amounts, but neither is fully receptor-specific: both also raised prolactin, ACTH, and cortisol to a degree comparable to a direct corticotropin-releasing-hormone challenge².

A real, narrow, foreign regulatory approval — stated at the scope it earned

Checked directly against a 2026 peer-reviewed review rather than assumed from marketing copy: pralmorelin "has an established clinical diagnostic role in Japan, as a pharmacologic stimulus to assess growth hormone deficiency and hypothalamic-pituitary function¹." That is real — a named foreign regulatory use, administered as an intravenous stimulation test to measure whether a patient's pituitary can still release GH on demand. It is also precisely bounded: the same review immediately qualifies it, stating "beyond its established diagnostic application, broader therapeutic use of GHRP-2 remains limited and is not supported by widespread regulatory approval¹." This article reports both halves together — diagnostic-use approval in Japan is real; a general therapeutic approval anywhere, including in Japan for anything beyond that diagnostic test, is not.

The real human evidence: acute IV testing, chronic oral dosing, and a genuine ICU research program

Three separate, real human research threads exist for GHRP-2, each testing a different question. First, acute pharmacology: the direct IV comparison against hexarelin above confirms the mechanism translates to people, at a single dose, in healthy young and elderly adults². Second, chronic oral dosing in a clinical population: a 2003 study gave ten GH-deficient children an oral dose of 900 micrograms/kg twice daily for 12 months, finding a transient appetite increase in 7 of 10 patients during the first six months, with no statistically significant chronic effect on BMI by the study's end³ — real evidence GHRP-2 has measurable oral bioavailability in humans, distinct from the injectable route this article's calculator page below is built around. Third, and most substantial: a real, published, controlled human research program tested continuous IV GHRP-2 infusion — alone and combined with TRH and GnRH — in patients with prolonged critical illness, a population whose GH, thyroid, and gonadal axes are all suppressed. One study in 86 time-series measurements found GHRP-2 infusion, unlike GHRH or TRH alone, synchronized the normally-coupled release of GH, TSH, and prolactin that critical illness disrupts⁴. A follow-up randomized study in 33 critically ill men found the full three-hormone combination reactivated GH, thyroid, and gonadal axes simultaneously, with GHRP-2 infusion alone reactivating GH secretion and normalizing IGF-1 on its own⁵. Both are genuine controlled human studies, run in an ICU, not a fitness or longevity context — a meaningfully different research base than most compounds in this site's non-board corpus.

The FDA safety-page entry, reported at its full, precise wording

FDA's own live-fetched safety-risk page for compounded bulk drug substances carries a specific, dated GHRP-2 entry (September 29, 2023) that deserves to be quoted in full rather than summarized down to its most alarming clause: "Compounded drugs containing GHRP-2 for injectable and nasal administration may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. GHRP-2 also contains an unnatural amino acid, which adds to the complexity of peptide characterization. FDA is aware of reports of serious adverse events in patients who received GHRP-2, including increased insulin requirement to maintain the blood glucose level, death of critically ill study subjects, infection and pancreatitis, though causality has not been established⁶." Read plainly: this is FDA's own list of serious adverse-event categories associated with GHRP-2 exposure, immediately followed by FDA's own statement that causality has not been established for them. A live PubMed search for the research context this most plausibly traces to turns up exactly the ICU studies described above — Van den Berghe and colleagues' controlled trials of GHRP-2 in prolonged critical illness, a population that carries substantial background mortality, infection, and glycemic instability independent of any study drug⁴⁵. This article states that connection as informed context for a reader trying to understand where FDA's language likely originates, not as a confirmed causal finding — FDA itself does not make that claim, and neither does this article.

FDA's 503A Bulks List: a real, specific, third category

Separately from the safety-risk page above, FDA's current 503A Bulks List — the document that governs which bulk substances compounding pharmacies may legally use — lists "GHRP-2" by name, fetched live as a PDF and text-searched directly rather than assumed from a prior article's check. It sits under Category 3: "Bulk Drug Substances Nominated Without Adequate Support⁷." That is a real, distinct regulatory bucket, different from Category 1 (bulk substances FDA is actively evaluating) and Category 2 (the significant-safety-risk page quoted above) — Category 3 means someone formally nominated GHRP-2 for the compounding list, and FDA determined the nomination itself did not include enough supporting information to complete an evaluation, not that FDA affirmatively found it safe or unsafe. Separately, DailyMed's structured-product-label search returns zero results for both "GHRP-2" and "pralmorelin," and openFDA's Drugs@FDA database returns zero matches for "pralmorelin" as a generic name — no FDA-approved U.S. human drug product exists under either name, consistent with Japan's diagnostic-only approval never having been pursued for U.S. marketing. openFDA's FAERS database returns 4 total reports for "GHRP-2," live-queried for this article⁸ — a small but non-zero count.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell GHRP-2 — this site's own identity-layer research confirms it is not tagged to any reviewed seller. GHRP-2 is a genuinely mixed case in this corpus: it carries a real, named diagnostic approval in Japan, a real and substantial ICU research base testing IV infusion in critically ill patients, a real oral chronic-dosing study in children, and a specific, quoted FDA safety-page entry citing serious adverse-event reports whose causality FDA itself states has not been established. It has never received U.S. marketing approval in any form, and sits in FDA's "nominated without adequate support" compounding category rather than an approved or actively-evaluated one. Our reconstitution calculator does the vial-to-syringe arithmetic on the numbers you enter — it cannot confirm a vial matches Japan's approved diagnostic product or any studied ICU protocol, since neither exists as a U.S.-marketed reference. If you're researching this compound alongside its closest relatives, our GHRP-6 evidence review and our Hexarelin evidence review cover the two other ghrelin-receptor secretagogues most often compared against it, and our CJC-1295/Ipamorelin evidence review covers the newer-generation compound specifically engineered for more selective GH release than this earlier class.